Assessment of IgG antibodies to Pseudomonas aeruginosa in patients with cystic fibrosis by an enzyme-linked immunosorbent assay (ELISA) by Renan Marrichi Mauch et al.
Mauch et al. Diagnostic Pathology 2014, 9:158
http://www.diagnosticpathology.org/content/9/1/158RESEARCH Open AccessAssessment of IgG antibodies to Pseudomonas
aeruginosa in patients with cystic fibrosis by an
enzyme-linked immunosorbent assay (ELISA)
Renan Marrichi Mauch1, Cláudio Lúcio Rossi1, José Dirceu Ribeiro2, Antônio Fernando Ribeiro2,
Marcos Tadeu Nolasco da Silva2 and Carlos Emílio Levy1*Abstract
Background: The usefulness of serological tests for detection of P. aeruginosa pulmonary infection in cystic fibrosis
(CF) is controversial. Here, we assessed the value of detecting anti-P. aeruginosa IgG by a quantitative
enzyme-linked immunosorbent assay (ELISA) for identification of P. aeruginosa infection in patients with cystic fibrosis.
Methods: Serum concentrations of anti-P. aeruginosa IgG were assessed in 117 CF patients classified according to their
P. aeruginosa colonization/infection status (never colonized; free of infection; intermittently colonized and chronically
infected) and in 53 healthy subjects by the ELISA test standardized with the St-Ag:1–17 antigen.
Results: The rate of IgG seropositivity and the median of IgG concentrations of this antibody in patients chronically
infected were significantly higher than those found in the other CF groups and in the healthy control group.
Conclusion: Detection of anti-P. aeruginosa IgG can be an useful tool for identification of P. aeruginosa chronic infection
in patients with CF.
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Cystic fibrosis (CF) is the most common hereditary dis-
ease in the Caucasian population, with a wide range of
clinical and genetic variants [1]. The genetic defect oc-
curs in the CF transmembrane conductance regulator
(CFTR) gene, which codes for a protein that regulates
the transport of electrolytes across epithelial cell mem-
branes. Mutations in the CFTR gene affect sodium and
chloride ion transport, resulting in the disruption of the
ionic composition and volume of airway surface fluid.
This fluid is normally thin to allow removal of inhaled
microorganisms via ciliary action; however, in the presence
of CFTR mutations, it increases in volume and becomes
viscous, clogging the airways. As a result, microorganisms* Correspondence: celevy@fcm.unicamp.br
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unless otherwise stated.entering the distal airways are not cleared and can cause
chronic infections with progressive inflammation and re-
spiratory insufficiency [2]. The clinical outcomes are simi-
lar to those found in diffuse panbronchiolitis, chronic
obstructive pulmonary disease and idiopatic pulmonary
fibrosis [3-5].
Pseudomonas aeruginosa is an important pathogen in
nosocomial and opportunistic infections due to its high
intrinsic resistance to antibiotics and ability to develop
multidrug resistance, which lead to serious therapeutic
problems [6]. P. aeruginosa is the most important and
frequent pathogen in CF patients [2,7,8], responsible for
elevated morbidity and mortality [1-3]. When chronic
P. aeruginosa pulmonary infection is established, this
bacterium is practically impossible to be eradicated;
however, the elimination from the airways is possible by
early intervention with antibiotic therapy, as soon as
the pathogen settles in the organism. Thus, the promptLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sion of the pulmonary disease [9].
Detection of P. aeruginosa in the diagnostic routine is
made mostly through sputum culture; however, many
patients - especially children under seven years old- are
incapable of producing an expectorated sputum speci-
men. Bronchoalveolar lavage (BAL) is an option, but is
invasive and usually employed only when there is a com-
pelling reason to obtain a respiratory sample and other
approaches have failed [10,11]. More superficial samples
include oropharyngeal (OP) and cough swab [12,13]; how-
ever, the frequent insufficient samples obtained through
swabs can lead to false negative results and recent reports
have shown that OP swabs poorly reflect the lung micro-
biota [13,14]. The difficulty in obtaining representative
respiratory specimens from the airways of infants and
children indicates the need for the use of methods that
can complement or be an alternative to microbiological
culture [15].
Serological tests have been used to assist the identifi-
cation of P. aeruginosa infection in CF patients, particu-
larly in patients who do not produce sputum. Some
reports also suggest that serological tests may help in
the differentiation between intermittent colonization and
chronic infection [16,17].
The diagnostic value of serological tests for detection of
P. aeruginosa infection in cystic fibrosis is controversial,
with large variations in the sensitivity and specificity values
[18]. The aim of the present study was to assess the value of
detecting anti-P. aeruginosa IgG by a quantitative enzyme-
linked immunosorbent assay (ELISA) for identification of P.
aeruginosa infection in patients with cystic fibrosis.
Methods
Patients, controls and serum samples
Serum samples were obtained from 117 patients with con-
firmed CF diagnosis [19-21] who attended the cystic fibro-
sis ambulatory of the University Hospital, State University
of Campinas, São Paulo, Brazil. Of these 117 patients, 35
(22 male, 13 female; median age = 3.0 years) had never
been colonized with P. aeruginosa, 27 (8 male, 19 female;
median age = 8.2 years) were free of infection, 24 (16 male,
8 female; median age = 9.0 years) were intermittently colo-
nized and 31 (17 male, 14 female; median age = 14.7 years)
were chronically infected by the pathogen. Fifty-three
serum samples from pediatric patients and university stu-
dents (32 male, 21 female; median age = 9.7 years) without
CF and no previous history of P. aeruginosa infection were
used as controls.
Bacteriology and classification of the patients according
to microbiological culture
The lower airway secretion was obtained by sputum ex-
pectoration in an universal sterile container. In case ofnon-expectorating patients, secretion of the upper air-
ways was collected with OP swab and transported to the
laboratory within 3 h. Microbiological culture and iden-
tification were performed according to methodology
previously described [7]. To classify the CF patients
according to their P. aeruginosa colonization/infection sta-
tus, we used an adaptation of the Leeds criteria [8], basing
on the results of 12 last respiratory microbiological cul-
tures prior to the blood sample collection, considering cul-
tures were made every three month. Thus, we classified
the patients as: (1) chronic infection, when ≥ 50% of the
cultures were positive to P. aeruginosa, (2) intermittent
colonization, when < 50% of the cultures were positive to
P. aeruginosa, (3) free of infection, when the last 12 cul-
tures were negative to P. aeruginosa with a previous posi-
tive culture and (4) never colonized, when P. aeruginosa
was never isolated in microbiological culture.
Determination of optimum assay conditions
The ELISA was standardized by using excess amounts of
all reagents except the one being tested. A pooled human
standard antiserum (Statens Serum Institute, Copenhagen,
Denmark) diluted 1:200 was arbitrarily designed as having
1000 activity antibody units per milliliter (U/mL). Arti-
ficial serum standards containing different antibody con-
centrations (U/mL) were prepared by diluting this
antiserum with phosphate buffered saline containing 0.1%
Tween 20 (PBS-T). For the St-Ag:1–17 antigen (Statens
Serum Institute, Copenhagen, Denmark) and conju-
gate (peroxidase-labeled rabbit anti-human IgG, Dako,
Glostrup, Denmark) titrations, dilutions from 1:250 to
1:64000 were tested. The linearity of substrate conversion
was assayed at time intervals from 1 to 60 min, using
serum standards containing 25 and 100 U/mL.
ELISA for detection antibodies to P. aeruginosa
The antigen preparation diluted 1:2000 in 0.1 M
carbonate-bicarbonate buffer, pH 9.5, was used to
sensitize wells of Maxisorp ELISA plates (Thermo Fisher,
Waltham, MA, United States). After sensitization for 1 h
30 min at room temperature (RT), the wells were
washed three times with PBS-T, after which 100 μl of
0.1% bovine serum albumin in 0.1% PBS-T were added
to the wells. After incubation for 1 h at RT, the wells
were washed twice with PBS-T and 100 μl of each serum
sample diluted 1:800 in PBS-T were added in triplicate
to the wells. After a further 1 h incubation at RT and
washing three times with PBS-T, 100 μl of conjugate di-
luted 1:4000 in PBS-T were added to the wells and the
plates were incubated for 1 h at RT. After incubation
and five washes with PBS-T, 100 μl of substrate system
(0.42 mM tetramethylbenzidine and 1.42 mM H2O2 in
0.1 M sodium acetate/acetic acid buffer, pH 5.5) were
added to the wells. Ten minutes after the addition of the
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to stop the color reaction and the resulting absor-
bances were read at 450 and 630 nm in an ELISA reader
(Labsystems, Helsinki, Finland). A negative control and
artificial positive serum standards containing different
concentrations of the antibody were included in each
ELISA plate. The final optical density for each well was
determined by subtracting the mean optical density of
two antigen controls in the corresponding plate. All
serum samples and positive standards were tested in trip-
licate and the mean activity determined. A standard
curve was used to translate optical density readings of
each serum specimen into U/mL.
Definition of the results status
The cut-off value for the assay was determined by a re-
ceiver operating characteristic (ROC) curve, using the
ELISA results obtained with CF patients chronically in-
fected with P. aeruginosa and healthy subjects. Analyz-
ing the results obtained with different dilutions of serum
samples from chronically infected patients, a variation
of 5% was applied to the cut-off value to define three
areas of test results - positive, negative and a grey zone
between them.
Statistical analyses
The Chi-square test was used to compare the rates of
IgG seropositivity among the CF patients and healthy
controls simultaneously; a confidence interval of 95%
was adopted. With respect to the medians of the anti-
body concentrations, the Mann–Whitney test and the
Kruskal Wallis test were used for comparisons between
two groups and more than two groups, respectively. The
Spearman test was used to identify correlation between
antibody levels and age of CF patients chronically infected
with P. aeruginosa. In all tests, a p value < 0.05 was consid-
ered statistically significant. The statistical analyses were
done using SAS (Statistical Analysis System) for Windows
version 9.2 (SAS Inc., Cary, NC, United States).
Results
Titration experiments defined 1:2000 and 1:4000 as the
optimal dilutions of antigen and conjugate, respectively.
The linearity studies showed that the substrate conver-
sion rates were linear for at least 10 min for standards
containing 25 and 100 U/mL. The cut-off value for specific
P. aeruginosa-IgG antibodies determined by the ROC curve
was 14.57 U/mL. Applying a 5% of variation to this cut-off,
negative, grey zone, and positive test results were defined
as < 13.8 U/mL, 13.8 to 15.3 U/mL and > 15.3 U/mL.
A total of 170 serum samples, 117 from CF patients
and 53 from healthy subjects, were assayed for anti-P.
aeruginosa IgG. Table 1 presents the demographic char-
acteristics of CF patients and healthy controls, as well asthe rate of positivity for anti-P. aeruginosa IgG in all
groups. Positive results were found in 1/35 (2.9%) of the
CF patients never colonized, in 3/27 (11.1%) of patients
free of infection, in 8/24 (33.3%) of patients intermit-
tently colonized, in 30/31 (96.8%) of patients chronically
infected and in one healthy control (1.9%). The rate of
IgG seropositivity in patients chronically infected was
significantly higher than those found in the other CF
groups and in the healthy control group (p < 0.0001). The
rate of IgG seropositivity in intermittently colonized CF
patients was significantly higher than those found in CF
patients never colonized and in the healthy controls (p <
0.001). Figure 1 shows the medians of IgG concentrations
(U/mL) in CF patients and healthy controls. The median
of IgG concentration in patients chronically infected was
significantly higher than those found in the other CF
groups and in the healthy control group (p < 0.0001). No
significant differences were found between healthy con-
trols and CF patients free of infection (p = 0.232), be-
tween healthy controls and CF patients never colonized
(p = 0.062) and between CF patients free of infection and
those with intermittent colonization (p = 0.064). A positive
correlation between antibody levels and age was found
in chronically infected CF patients by the Spearman test
(r = 0.40; p < 0.01).
Discussion
The antibody response to P. aeruginosa in cystic fibrosis
has been considered a marker of chronic infection, in-
flammation and tissue damage [22,23]. In the last three
decades, several studies have shown the potential of
antibody detection for early diagnosis of P. aeruginosa
pulmonary infection [15-18] in order to initiate the early
eradication therapy [23].
The standardization of a quantitative ELISA for detec-
tion of specific antibodies requires that the concentra-
tions of all reagents and reaction times be optimized. It
is important the measurement of enzymatic activity dur-
ing the linear part of the reaction, when substrate con-
centration is much higher than enzyme concentration.
The standardization of the assay involves the use of a posi-
tive standard from which a standard curve is prepared and
included in each ELISA plate, with the reactivity of the
samples being tested determined from the standard curve.
The utilization of a standard curve in every reaction plate
reduce the variability of the assay [24,25].
In our study, the rate of anti-P.aeruginosa IgG sero-
positivity and the concentration of this antibody were
significantly higher in the patients chronically infected
than those in the other CF groups, corroborating previous
studies that showed high frequency of detection and ele-
vated levels of this antibody in this phase of infection
[18,26,27]. One serum sample from a CF patient with
chronic infection by P. aeruginosa who was under
Table 1 Gender, age and detection of anti-P. aeruginosa IgG in patients with cystic fibrosis and in healthy controls
Parameters
Subject groups
CF chronic infection CF intermittent colonization CF free of infection CF never colonized Healthy controls
Number of subjects 31 24 27 35 53
Gender (M/F) 17/14 16/8 8/19 22/13 32/21
Median age - years (range) 14.7 (3 – 30) 9.0 (1.6 – 16) 8.2 (3 – 25) 3.0 (0.16 – 26) 9.7 (0.16 – 30)
% IgG seropositivity [C.I. 95%] 96.8 (81.5 – 99.8) 33.3 (16.4 – 55.3) 11.1 (2.9 – 30.3) 2.9 (0.2 – 16.6) 1.89 (0.1 – 11.4)
The rate of IgG seropositivity in patients chronically infected was significantly higher than those found in the other CF groups and in the healthy control group
(p < 0.0001). The rate of IgG seropositivity in intermittent colonized patients was significantly higher than those found in CF patients never colonized and in the
healthy controls (p < 0.001).
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pathogen. Some studies have shown that antibiotic treat-
ment regimens may result in decrease of the antibody
levels to P. aeruginosa [28-30].
A healthy control with no history of P. aeruginosa
infection showed a positive serology to the pathogen.
Previous reports showed the occurrence of false negative
results [22,31-33]. Since P. aeruginosa is an environ-
mental pathogen, it is possible that this healthy control
have got in contact with this bacterium in a period nextFigure 1 Serum concentrations of anti-P. aeruginosa IgG (U/mL) in pa
infection status and in healthy controls. The median of IgG concentratio
found in the other CF groups and in the healthy controls (p < 0,0001). No s
intermittently colonized and free of infection, between CF patients free of
colonized and the control group.to the study, leading to a transient antibody response
[23,26]. Some authors have also shown that the St-
Ag:1–17 preparation contains antigens which are cross-
reactive with other gram-negative bacteria, including
Haemophilus influenzae [17,28], which is a common
microorganism in the respiratory tract of healthy children
and adults. Høiby et al. [22] and Pedersen et al. [33] ob-
served, in healthy controls, an increase in the antibody
levels over the age. They attribute these facts to the normal
occurrence of cross reactions with other pathogens andtients classified according to their P. aeruginosa colonization/
n in patients chronically infected was significantly higher than those
tatistically significant differences were found between CF patients
infection and the control group and between CF patients never
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contact with P. aeruginosa.
It has been known for many years that chronic P. aerugi-
nosa infection is preceded by an intermittent colonization
with the pathogen and previous reports showed an overlap
in the antibody levels between chronically infected and
intermittent colonized CF patients [16,26,28]. In the
present study, we did not find statistical difference in the
antibody titers between the intermittently colonized and
the free of infection group. Indeed, the majority (66.7%) of
intermittently colonized patients had negative serology to
P. aeruginosa; however, it is well known that P. aeruginosa
isolation in respiratory samples not necessarily indicates in-
fection, unless there is a specific humoral response [8,34].
In some patients, the colonization can persist for 1 to
2 years without eliciting an humoral immune response
[33], which can be due to the presence of transient or non
pathogenic strains, to the inadequate immune response to
the pathogen [28], or even to the adequate immune re-
sponse of the patient through secretory IgA [23,28]. Be-
sides, there is a great interchange of patients between these
two groups when longitudinal microbiological data are ob-
served [26]. On the other hand, the positive antibody levels
of 33.3% of the intermittently colonized patients in the
present report may suggest a change in the colonization/
infection status for chronically infected [16,17]. These re-
sults draw attention to limitations in the Leeds criteria for
definition of colonization and infection status [8], which
are based solely on microbiological cultures. Serology re-
sults, in conjunction with more frequent respiratory cul-
tures, can play an important role in elaborating a better
definition for colonization and infection, mainly for pa-
tients classified as free of infection and intermittently colo-
nized [16,17,26,35].
Among the CF patients with negative microbiological
respiratory culture, the rate of seropositivity was 2.9%
and 11.1% in the never colonized group and the free of
infection group, respectively. Such findings may suggest
limitations in respiratory culture, which may not reflect
the lung microbiota [11,13,14], or even recurrent infection
[27,34]. Many of these patients are not sputum producers,
making more difficult to obtain representative respiratory
samples, which may lead to false negative results. So, these
groups constitute an important focus of interest for detec-
tion of serum anti-Pseudomonas antibodies [29].
A large variation in the performances of immunological
assays used for the diagnosis of P. aeruginosa infection in
CF patients has been observed [18], which is expected and
is related to several factors including the antigen chosen,
the criteria used for selection of the patients and healthy
controls, the criteria adopted for classification of the
colonization/infection status, the immune status of the pa-
tients at time of blood collection, the antibiotic treatment
regimen, the intrinsic properties of the serological methodsused for antibody detection, the antigen preparation, the
lack of an appropriate reference standard and the method
for calculating the cut-off value [18,30,36]. Here, we con-
sidered that culture results of one year prior to the sero-
logical analysis were not enough to provide a consistent
classification of P. aeruginosa colonization/infection status.
So, we used the 12 last culture results, seeking to optimize
this classification. For classification according to serological
results, we fixed negative and positive cut-off values
through a ROC analysis, based on the results of a healthy
population. This may help to avoid bias when determining
the accuracy of the method [30,36]. The St-Ag:1–17 anti-
gen was chosen by the fact of being a commercialized anti-
gen; besides, the studies with the St-Ag:1–17 has been
continuous over the last 30 years. Other antigens, like exo-
toxin A, elastase and alkaline protease are quorum-sensing
regulated antigens [17] and require a higher bacterial load
to elicit the immune response. Since St-Ag:1–17 consti-
tutes a pool of 64 antigens from 17 different P. aeruginosa
serotypes, the immune response is earlier in relation to
these other antigens [17,23].Conclusions
This report has the limitations of a cross-sectional study.
Since that only one serum sample was obtained from each
patient, we could not take further conclusions. Longitu-
dinal reports have demonstrated the capacity of serology
to detect P. aeruginosa infection until three years before
microbiological culture [18]. Future protocols based in
longitudinal studies in our laboratory should verify the
importance of our findings. Besides, other diagnostic re-
sources must be evaluated, like real-time PCR of respira-
tory samples, culture of paranasal sinuses secretions, the
humoral response to other antigens and the secretory IgA
response. Overall, the results of the present study show
that the ELISA for detection of anti-P. aeruginosa IgG can
be an useful tool for identification of P. aeruginosa chronic
infection in patients with cystic fibrosis.Ethical approval
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